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Imperial College at Charing Cross Campus, Vascular Surgery Research Group,
St Dunstan’s Road, London W6 8RP, UKThe medical management of peripheral arterial
disease, including intermittent claudication, has been
a favourite topic for reviews in the last few years:
a good recent synthesis of available evidence is by
Hankey et al.1 PREPARED-UK has attempted to audit
the medical treatment of patients newly referred with
intermittent claudication in 2002e3. The audit cycle
works by comparing current practice to recommended
practice and identifying mechanisms to improve prac-
tice before a further audit, which hopefully will show
improvement.
Perhaps the key messages of PREPARED-UK are
that 4e5 years ago blood pressure in patients with
intermittent claudication was poorly controlled and
that less than half were prescribed statins.2 Sometimes
what remains unsaid is more important than what is
said. The authors have acknowledged the principal
weaknesses of their study: it was a highly selected
cohort of patients and a few had even undergone pre-
vious vascular surgery.
First the patients supposedly were newly referred
to vascular surgical clinics with symptoms of inter-
mittent claudication. In many such instances the
family practitioner should provide help with smoking
cessation but might be reluctant to initiate new (often
expensive) drug therapy, until the diagnosis has been
confirmed or excluded by measurement of ankle pres-
sures and other diagnostic tests as necessary. There-
fore, we need greater clarity about the role and
responsibilities of prescribing for patients with pe-
ripheral arterial disease. Medical management needs
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leg symptoms and the prevention of the systemic
complications of generalised atherosclerosis. Guide-
lines for these issues should be developed at national
and European level. One critical question not ad-
dressed by PREPARED-UK is whether the medical
treatment of intermittent claudication had been im-
proved after the diagnostic visit to a vascular surgical
service? Surely the vascular surgeon and vascular
nurse should become responsible for indicating the
best medical management of their patients and not
rely on prior treatment by the family practitioner.
Second the only drug which specifically targets the
improvement of leg symptoms, cilostazol, has not
been mentioned. A meta-analysis of 8 randomised
controlled trials in over 2500 patients has shown
that cilostazol improves maximum walking distance
and pain-free walking distance.3 Cilostazol, a phos-
phodiesterase inhibitor, also inhibits platelet aggre-
gation and generally is well tolerated (although
contraindicated in those with heart failure).
Third prescribing for these mainly elderly patients,
who are likely to be taking drugs to treat other condi-
tions, must be rationalised. Polypharmacy can lead
to excess adverse drug interactions, costs and poor
compliance.4 These factors must be considered when
guidelines for medical management of intermittent
claudication are formulated.
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